Safety and Efficacy of Teduglutide After 52 Weeks of Treatment in Patients With Short Bowel Syndrome Intestinal Failure
|
|
- Derek Martin
- 5 years ago
- Views:
Transcription
1 Safety and Efficacy of Teduglutide After 52 Weeks of Treatment in Patients With Short Bowel Syndrome Intestinal Failure O keefe, S.J.D et al, Clinical Gastroenterology and Hepatology Accepted date: 21 December 2012
2 Background Loss of 50% of small intestine is well tolerated Intestinal failure occurs when >70% of small intestine and colon or >80% of small intestine has been lost Natural adaption due to peptide hormones: hypertrophy of gut and hyperplasia of mucosal surface (villous hyperplasia) Growth hormone: increases energy absorption, acromegaly Glucagon-like peptide-2 (GLP-2): villous hypertrophy, retards gastric secretion/emptying, increases mucosal blood flow/absorption Teduglutide: GLP-2 analog, longer half-life Bible class
3 Methods study design Patients who completed a 24-week randomized, double blind, placebo-controlled, parallel group, multicenter study of teduglutide (0.05mg/kg/d or 0.1mg/kg/d) Conclusion: Teduglutide was safe, well tolerated, intestinotrophic and suggested pro-absorptive effects facilitating reductions in parenteral support in patients with SBS with intestinal failure Jeppesen et al, Gut 2011;60: Bible class
4 Methods study design 32 centers in US, Canada, Denmark, France, Poland, Germany, Netherlands, UK, Belgium 28-week double-blind extension study, total treatment 52w Patients randomized to teduglutide initially continued with same dose Bible class
5 Methods exclusion criteria <18y cancer or lymphoproliferative disease Pregnancy / lactation active Crohn s disease radiation enteritis Scleroderma celiac disease alcohol/drug abuse allergy to teduglutide no use of immunomodultators, GH or GLP-2 in the last 12 weeks Bible class
6 Methods inclusion criteria >18y On parenteral nutrition SBS secondary to Crohn s disease, volvulus, injury, vascular ischaemia Remnant small bowel <150cm No suspicion of active inflammatory bowel disease or fistulas No history of radiation enteritis or sprue No alcohol/drug abuse No significant renal/hepatic/cardiac disease No glutamin/gh Bible class
7 Methods use of parenteral nutrition PN optimization and stabilization where IV fluids were adjusted until urine output 1-2L/d with >20mEq of sodium and blood creatitin normal Randomization teduglutide or placebo once daily for 24 weeks Efficacy of drug assessed by ability to reduce IV fluid requirements to maintain constant urine output PN reduced at 4-week intervalsif 48h urine output increased by 10% After 24 weeks willing patients continued for additional 28 weeks Bible class
8 Aim of the study Evaluation of long term safety, tolerability and efficacy of daily teduglutide for 52 weeks Bible class
9 Patient characteristics Bible class
10 Safety and tolerability Bible class
11 Efficacy 0.05: -4.9L/w (52%) 0.1: -3.3L/w (26%) Bible class
12 Efficacy Bible class
13 Discussion Efficacy not only maintained but increased after 52w Adverse event profile satisfactory Number of PN infusions per week could be reduced In 4 PN could be stopped Fasting plasma citrulline raised as sign of increased enterocyte mass (68% in 0.05, 86% in 0.1, significant) Animal models: GLP-2 in supraphysiologic doses may enhance rather than induce tumor growth longer studies needed Drug absorption is likely to be increased on teduglutide Reduction of PN translates to an inprovement of quality of life Bible class
Management of Short Bowel Syndrome in the Era of Teduglutide. Charlene Compher, PhD, RD University of Pennsylvania
Management of Short Bowel Syndrome in the Era of Teduglutide Charlene Compher, PhD, RD University of Pennsylvania compherc@nursing.upenn.edu Disclosures Research funding for clinical trials by NPS Pharmaceuticals
More informationParenteral Nutrition. Outline. Potential Biomarkers for Use in Intestinal Adaptation. Jejunum is primary site of digestion and absorption
Outline Potential Biomarkers for Use in Intestinal Adaptation Kelly A. Tappenden, Ph.D., R.D. Professor of Nutrition and GI Physiology 1. Intestinal Adaptation potential regulators 2. Intestinal mucosal
More informationSafety and Efficacy of Teduglutide After 52 Weeks of Treatment in Patients With Short Bowel Intestinal Failure
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2013;11:815 823 Safety and Efficacy of Teduglutide After 52 Weeks of Treatment in Patients With Short Bowel Intestinal Failure STEPHEN J. D. O KEEFE,* PALLE B.
More informationEmerging Strategies for the Management of Intestinal Failure
Emerging Strategies for the Management of Intestinal Failure Kelly Tappenden, PhD, RD, FASPEN Human Nutrition Endowed Professor University Distinguished Teacher-Scholar Provost Fellow University of Illinois
More informationGATTEX (Teduglutide) for Injection REMS Program: Prescriber Education
GATTEX (Teduglutide) for Injection REMS Program: Prescriber Education Shire-NPS Pharmaceuticals, Inc. 300 Shire Way, Lexington, MA 02421 A REMS (Risk Evaluation and Mitigation Strategy) is a program required
More informationESPEN Congress Florence 2008
ESPEN Congress Florence 2008 PN Guidelines presentation PN Guidelines in gastroenterology A. van Gossum (Belgium) ESPEN-Parenteral Guidelines in Gastroenterology André Van Gossum, Eduard Cabre, Xavier
More informationAGENDA. Business highlights Significant progress with late stage clinical programs heading towards filing. Britt Meelby Jensen
AGENDA Business highlights Significant progress with late stage clinical programs heading towards filing The Zealand peptide platform World leading expertise delivering differentiated peptide-based drug
More informationGattex. Gattex (teduglutide) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.50.03 Subject: Gattex Page: 1 of 5 Last Review Date: March 16, 2018 Gattex Description Gattex (teduglutide)
More informationGattex. Gattex (teduglutide) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.09.03 Subject: Gattex Page: 1 of 5 Last Review Date: September 18, 2015 Gattex Description Gattex (teduglutide)
More informationNUTRITION ISSUES IN GASTROENTEROLOGY, SERIES #68. Growth Hormone, Glutamine and Glucagon-like Peptide 2 in Short Bowel Syndrome
Carol Rees Parrish, R.D., M.S., Series Editor Growth Hormone, Glutamine and Glucagon-like Peptide 2 in Short Bowel Syndrome Palle Bekker Jeppesen By definition, intestinal failure prevails when oral compensation
More informationteduglutide [rdna origin] (Gattex )
Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided
More informationDefinition and Types of Intestinal Failure
Definition and Types of Intestinal Failure Jeremy Nightingale Consultant Gastroenterologist St Mark s Hospital Intestinal Failure - Definitions Reduction in functioning gut mass below the minimum amount
More informationAn otherwise healthy 45 year-old man underwent
Carol Rees Parrish, M.S., R.D., Series Editor Short Bowel Syndrome in Adults Part 5 Trophic Agents in the Treatment of Short Bowel Syndrome John K. DiBaise Carol Rees Parrish An important goal when treating
More informationGATTEX (teduglutide [rdna origin])
GATTEX (teduglutide [rdna origin]) Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices
More informationShort Bowel Syndrome: Medical management
Short Bowel Syndrome: Medical management La Sindrome dell'intestino Corto in età pediatrica Brescia 18 marzo 2011 Jon A.Vanderhoof, M.D. Division of Pediatric GI Harvard Medical School Children s Hospital,
More informationBritish Intestinal Failure Alliance (BIFA) position statement: Use of peptide growth factors for adult patients with intestinal failure.
British Intestinal Failure Alliance (BIFA) position statement: Use of peptide growth factors for adult patients with intestinal failure. By Siddhartha Oke, Jeremy Nightingale, Palle Jeppesen and the BIFA
More informationEnteral and parenteral nutrition in GI failure and short bowel syndrome
Enteral and parenteral nutrition in GI failure and short bowel syndrome Alastair Forbes University College London Intestinal failure Inadequate functional intestine to allow health to be maintained by
More informationNutritional Requirements in Intestinal Failure
Nutritional Requirements in Intestinal Failure Christopher Duggan, MD, MPH Center for Nutrition Center for Advanced Intestinal Rehabilitation (CAIR) Division of Gastroenterology, Hepatology and Nutrition
More informationDeveloping treatment options for patients with rare gastrointestinal and endocrine disorders and unmet medical need
Developing treatment options for patients with rare gastrointestinal and endocrine disorders and unmet medical need Luke Beshar, senior vice president and chief financial officer BioNJ BioPartnering 2011
More informationShort bowel syndrome (SBS) causes severe. Seeking Enteral Autonomy with Teduglutide NUTRITION ISSUES IN GASTROENTEROLOGY, SERIES #167 INTRODUCTION
Seeking Enteral Autonomy with Carol Rees Parrish, M.S., R.D., Series Editor Andrew P. Copland Brian Behm Carol Rees Parrish Patients with short bowel syndrome (SBS) often struggle to maintain nutrition
More informationOutcomes from a 12-Week, Open-Label, Multicenter Clinical Trial of Teduglutide in Pediatric Short Bowel Syndrome.
Outcomes from a 12-Week, Open-Label, Multicenter Clinical Trial of Teduglutide in Pediatric Short Bowel Syndrome. Carter BA 1, Cohran VC 2, Cole CR 3, Corkins MR 4, Dimmitt RA 5, Duggan C 6, Hill S 7,
More informationOn the horizon: trophic peptide growth factors as therapy for neonatal short bowel syndrome.
ISSN: 1472-8222 (Print) 1744-7631 (Online) Journal homepage: http://www.tandfonline.com/loi/iett20 On the horizon: trophic peptide growth factors as therapy for neonatal short bowel syndrome. Patricia
More informationShort Bowel Syndrome and Intestinal Failure: Consensus Definitions and Overview
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2006;4:6 10 REVIEWS Short Bowel Syndrome and Intestinal Failure: Consensus Definitions and Overview STEPHEN J. D. O KEEFE,* ALAN L. BUCHMAN, THOMAS M. FISHBEIN,
More informationESPEN Congress Brussels Dietary and pharmacological therapy of Intestinal Failure. Bernard MESSING
ESPEN Congress Brussels 2005 Dietary and pharmacological therapy of Intestinal Failure Bernard MESSING Dietary and pharmacological therapy of Intestinal Failure Professeur Bernard MESSING HOPITAL LARIBOISIERE
More informationThe top 5 things all doctors should know about nutrition. Dr Peter Mooney Consultant Gastroenterologist Leeds Teaching Hospitals NHS Trust
The top 5 things all doctors should know about nutrition Dr Peter Mooney Consultant Gastroenterologist Leeds Teaching Hospitals NHS Trust ONE NUTRITION IS EVERYONE S PROBLEM 2018 2006 2013 2010 Mortality
More informationFistuloclysis (distal limb feeding) Dr Alison Culkin Research Dietitian AuSPEN 2015
Fistuloclysis (distal limb feeding) Dr Alison Culkin Research Dietitian AuSPEN 2015 Overview Consider the evidence Describe the practicalities Present some cases Fistuloclysis/distal limb feeding Infusion
More informationLong-Term Teduglutide for the Treatment of Patients With Intestinal Failure Associated With Short Bowel Syndrome
Citation: (2016) 7, e142; doi:10.1038/ctg.2015.69 & 2016 the American College of Gastroenterology All rights reserved 2155-384X/16 www.nature.com/ctg Long-Term Teduglutide for the Treatment of Patients
More informationSponsor. Generic Drug Name. Trial Indication(s) Protocol Number. Protocol Title. Clinical Trial Phases. Study Start/End Dates
Sponsor Novartis Generic Drug Name Lumiracoxib Trial Indication(s) Safety study effects on small bowel Protocol Number CCOX189A2425 Protocol Title A 16-day, randomized, double-blind, double-dummy, placebo-controlled,
More informationNon-Invasive Assessment of Intestinal Function
Overview Non-Invasive Assessment of Intestinal Function Introduction This paper will demonstrate that the 13 C-sucrose breath test ( 13 C-SBT) determines the health and function of the small intestine.
More informationNutritional Support outside the Hospital: Home Parenteral Nutrition (HPN) in Adult Patients Topic 19
Nutritional Support outside the Hospital: Home Parenteral Nutrition (HPN) in Adult Patients Topic 19 Module 19.1 Indications and Outcome Learning Objectives André Van Gossum Head of the Clinic of Intestinal
More informationNutritional Support outside the Hospital: Home Parenteral Nutrition (HPN) in Adult Patients Topic 19
Nutritional Support outside the Hospital: Home Parenteral Nutrition (HPN) in Adult Patients Topic 19 Module 19.1 Indications and outcome André Van Gossum Learning objectives: Learning about indications
More informationMucosal Healing in Crohn s Disease. Geert D Haens MD, PhD University Hospital Gasthuisberg University of Leuven Leuven, Belgium
Mucosal Healing in Crohn s Disease Geert D Haens MD, PhD University Hospital Gasthuisberg University of Leuven Leuven, Belgium Mucosal Lesions in CD: General Features CD can affect the entire GI tract
More informationList of Topics and Modules (2012)
List of Topics and Modules (202) Code Title Credits for Live course Topic 0 Introduction to Clinical Nutrition EDU T0 M 0. Introduction to clinical nutrition support Topic Metabolism of Metabolism of Macronutrients,
More informationFluid management in short bowel & intestinal failure. Dr Simon Gabe Consultant Gastroenterologist St Mark s Hospital
Fluid management in short bowel & intestinal failure Dr Simon Gabe Consultant Gastroenterologist St Mark s Hospital Variability of intestinal length Technique Author n Small intestinal length, m Mean Range
More informationIntestinal Rehabilitation and Transplantation
Intestinal Rehabilitation and Transplantation Joel Lim, MD Associate Professor of Pediatrics Children s Mercy Hospital University of Missouri in Kansas City Objective: Intestinal Failure/Short Bowel Syndrome
More informationSIBO
SIBO What is it? Small Intestinal Bowel Overgrowth A chronic bacterial infection of the small intestine Caused by bad bacteria such as E Coli and Clostridium migrating to the small intestine There is not
More information(12) United States Patent
USOO9545434B2 (12) United States Patent Sanguinetti et al. () Patent No.: (45) Date of Patent: US 9,545.434 B2 *Jan. 17, 2017 (54) TREATMENT OF SHORT BOWEL SYNDROME PATIENTS WITH COLON-IN-CONTINUITY (71)
More informationINTESTINAL FAILURE, REHABILITATION & TRANSPLANTATION: Indications, Techniques and Outcomes
INTESTINAL FAILURE, REHABILITATION & TRANSPLANTATION: Indications, Techniques and Outcomes Douglas G. Farmer, MD. Professor of Surgery Director, Intestinal Transplant Program Dumont-UCLA Transplant Center
More information2. Have your symptoms affected your ability to carry out your daily activities? YES NO
QUESTIONNAIRE Page 1 of 5 Date: Referring MD (Name, Address, Phone Number): Primary Care Physician (Name and Address, Phone Number): Reason for visit: 1. How long have you had symptoms? Describe your symptoms?
More informationESPEN LLL Programme in Clinical Nutrition and Metabolism. List of Topics and Modules 2014
ESPEN LLL Programme in Clinical Nutrition and Metabolism List of Topics and Modules 204 Code Title Credits for Live course Credits for on-line course Credits for Grading Quiz Topic 0 Introduction in Nutrition
More informationSummary of Results for Laypersons
What was the Study Called? Summary of Results for Laypersons A Randomized, Double-blind, Parallel-group, Placebo- and Active-controlled, Multicenter Study to Evaluate the Efficacy, Safety and Tolerability
More informationNew Findings in Nutritional Gastroenterology
New Findings in Nutritional Gastroenterology Stephen J O Keefe MBBS, MD, MSc, FRCP Division of Gastroenterology, Department of Medicine University of Pittsburgh Talk Outline Does nutritional support improve
More informationSpeaker Introduction
Speaker Introduction Stephen B. Hanauer, MD Professor of Medicine and Clinical Pharmacology University of Chicago Pritzker School of Medicine Chief of Gastroenterology, Hepatology, and Nutrition University
More informationNutritional Management in Enterocutaneous fistula Dr Deepak Govil
Nutritional Management in Enterocutaneous fistula Dr Deepak Govil MS, PhD (GI Surgery) Senior Consultant Surgical Gastroenterology Indraprastha Apollo Hospital New Delhi What is enterocutaneous fistula
More informationfollowing the last documented transfusion; thereafter, evaluate the residual impairment(s).
Adult Listings 5.01 Category of Impairments, Digestive System 5.02 Gastrointestinal hemorrhaging from any cause, requiring blood transfusion (with or without hospitalization) of at least 2 units of blood
More informationShort bowel syndrome after cytoreductive surgery and HIPEC: nutritional considerations
JBUON 2014; 19(2): 549-553 ISSN: 1107-0625, online ISSN: 2241-6293 www.jbuon.com E-mail: editorial_office@jbuon.com ORIGINAL ARTICLE Short bowel syndrome after cytoreductive surgery and HIPEC: nutritional
More informationSynopsis. Adalimumab M Clinical Study Report R&D/09/060. (For National Authority Use Only) to Part of Dossier: Name of Study Drug:
Synopsis Abbott Laboratories Name of Study Drug: Individual Study Table Referring to Part of Dossier: Volume: (For National Authority Use Only) Name of Active Ingredient: Page: Title of Study: A Multi-Center,
More informationHigh-output stoma after small-bowel resections for Crohn s disease
High-output stoma after small-bowel resections for Crohn s disease Stephen KK Tsao*, Melanie Baker, Jeremy MD Nightingale SUMMARY Background A 56-year-old Caucasian woman with a history of Crohn s disease
More informationMalabsorption: etiology, pathogenesis and evaluation
Malabsorption: etiology, pathogenesis and evaluation Peter HR Green NORMAL ABSORPTION Coordination of gastric, small intestinal, pancreatic and biliary function Multiple mechanisms Fat protein carbohydrate
More informationPhosphoremia (mmol/l) Calcemia (mmol/l) Postnatal age (days) Postnatal age (days) Urinary Calcium (mg/kg/d) Phosphoremia (mmol/l)
3,0 3,2 Calcemia (mmol/l) 2,8 2,6 2,4 2,2 2,0 1,8 Phosphoremia (mmol/l) 3,0 2,8 2,6 2,4 2,2 2,0 1,8 1,6 1,4 1,2 1,6 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 Postnatal age (days) 1,0 0 1 2 3 4 5 6 7 8 9 10 11
More informationA study to test whether BI improves mental abilities in people with mild Alzheimer s disease and difficulties with mental functioning
A study to test whether improves mental abilities in people with mild Alzheimer s disease and difficulties with mental functioning This is a summary of a clinical study in Alzheimer s disease. It is written
More informationGastroenterology. Certification Examination Blueprint. Purpose of the exam
Gastroenterology Certification Examination Blueprint Purpose of the exam The exam is designed to evaluate the knowledge, diagnostic reasoning, and clinical judgment skills expected of the certified gastroenterologist
More informationChronic diarrhea. Dr.Nasser E.Daryani Professor of Tehran Medical University
1 Chronic diarrhea Dr.Nasser E.Daryani Professor of Tehran Medical University Timing Acute diarrhea: 4 weeks Definitions Derived from Greek
More informationLong term home parenteral nutrition or small bowel transplantation? Florence LACAILLE Necker-enfants malades, Paris
Long term home parenteral nutrition or small bowel transplantation? Florence LACAILLE Necker-enfants malades, Paris Intestinal failure : definitive Ultra-short bowel : ± < 30 cm - valve ± < 20 cm + valve
More informationAli Keshavarzian MD Rush University Medical Center, Chicago, IL
Ali Keshavarzian MD Rush University Medical Center, Chicago, IL Ulcerative colitis Crohn s disease Optimize Quality of Life Induce remission [treat flare up] Maintain remission [avoid flare up] Prevent
More informationSponsor Novartis. Generic Drug Name Vildagliptin/Metformin. Therapeutic Area of Trial Type 2 diabetes. Approved Indication Type 2 diabetes
Clinical Trial Results Database Page 1 Sponsor Novartis Generic Drug Name Vildagliptin/Metformin Therapeutic Area of Trial Type 2 diabetes Approved Indication Type 2 diabetes Study Number CLMF237A2309
More informationFM CFS leaky gut April pag 1
FM CFS leaky gut April 21 2018 pag 1 FIBROMYALGIA / CHRONIC FATIGUE SYNDROME AND LEAKY GUT. SUMMARY OF CLINICAL TRIAL DESIGN. Double-blind randomized placebo-controlled challenge with gluten and milk protein
More informationSUSTAIN BASELINE DATA COLLECTION FORM. Revised 2/4/2014 (both pediatric and adult data elements) 1. Gestational age at birth ( weeks gestation)
SUSTAIN BASELINE DATA COLLECTION FORM Patient Demographics Revised 2/4/2014 (both pediatric and adult data elements) Did the patient begin Home PN over 90 days ago? Yes No Date began Home PN Patient Number
More informationthe only oral supplement so quick and effective:
The Product the only oral supplement so quick and effective: 30 days to increase ferritinemia and syderemia to +50% [90-120 days with common oral supplementation with iron]. After 1 week the subject will
More informationCapsule Endoscopy: Is it Really Helpful in the Diagnosis of Small Bowel Diseases? Kashif Malik, Muhammad Joher Amin, Syed Waqar Hassan Shah
Original Article Capsule Endoscopy: Is it Really Helpful in the Diagnosis of Small Bowel Diseases? Kashif Malik, Muhammad Joher Amin, Syed Waqar Hassan Shah ABSTRACT Objective: To determine the diagnostic
More informationParenteral Nutrition in IBD: Any indication?
Parenteral Nutrition in IBD: Any indication? Name: Institution: Marianna Arvanitakis Erasme University Hospital, Brussels, Belgium Clinical case 42 year old male Crohn s disease since he was 16 years old
More informationAppetite, Glycemia and Entero-Insular Hormone Responses Differ Between Oral, Gastric-Remnant and Duodenal Administration of a Mixed Meal Test After
Appetite, Glycemia and Entero-Insular Hormone Responses Differ Between Oral, Gastric-Remnant and Duodenal Administration of a Mixed Meal Test After Roux-en-Y Gastric Bypass June 2018 How a surgical complication
More informationPharmacy Prior Authorization Somatostatin Analogs Clinical Guideline
Sandostatin LAR (octreotide) Signifor (pasireotide) Signifor LAR (pasireotide) Somatuline Depot (lanreotide) octreotide FDA Approved Indications: Acromegaly: Octreotide Injection is indicated to reduce
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall
More informationHistologic Follow-up of People With Celiac Disease on a Gluten-Free Diet Slow and Incomplete Recovery
Anatomic Pathology / HISTOLOGIC FOLLOW-UP OF PEOPLE WITH CELIAC DISEASE ON A GLUTEN-FREE DIET Histologic Follow-up of People With Celiac Disease on a Gluten-Free Diet Slow and Incomplete Recovery Peter
More informationCitrulline as a marker of intestinal function and absorption in clinical settings: a systematic review and meta-analysis
Citrulline as a marker of intestinal function and absorption in clinical settings: a systematic review and meta-analysis Konstantinos Fragkos (1), Alastair Forbes (2) (1) University College London Hospitals,
More informationMedical Therapy for Pediatric IBD: Efficacy and Safety
Medical Therapy for Pediatric IBD: Efficacy and Safety Betsy Maxwell, MD Assistant Professor of Clinical Pediatrics Division of Gastroenterology, Hepatology, and Nutrition Pediatric IBD: Defining Remission
More informationESPEN Congress Glasgow A. Van Gossum
ESPEN Congress Glasgow 2002 ESPEN Guideline Reports HOME ARTIFICIAL NUTRITIONAL SUPPORT (HANS) Current status in Europe A. Van Gossum HOME ARTIFICIAL NUTRITIONAL SUPPORT (HANS) Current status in Europe
More informationGastroenterology Fellowship Program
Gastroenterology Fellowship Program Outpatient Clinical Rotations I. Overview A. Three Year Continuity Clinic Experience All gastroenterology fellows will be required to have a ½ day continuity clinic
More informationModerately to severely active ulcerative colitis
Adalimumab in the Treatment of Moderate-to-Severe Ulcerative Colitis: ULTRA 2 Trial Results Sandborn WJ, van Assche G, Reinisch W, et al. Adalimumab induces and maintains clinical remission in patients
More informationChief of Endocrinology East Orange General Hospital
Targeting the Incretins System: Can it Improve Our Ability to Treat Type 2 Diabetes? Darshi Sunderam, MD Darshi Sunderam, MD Chief of Endocrinology East Orange General Hospital Age-adjusted Percentage
More informationPRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION
PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION Pr REVESTIVE * Teduglutide for injection Powder for solution for injection 5 mg per vial Alimentary tract and metabolism products ATC Code: A16AX08
More informationDiseases in which appear swelling, redness, pain and heat; aspects of the immune system (Inflammatory and immunologic conditions-imid)
VI.2 Elements for a Public Summary VI.2.1 Overview of disease epidemiology Prednisolone is generally preferred amongst glucocorticoids for anti-inflammatory and immunosuppressive treatment. There are three
More informationCurrent Trends in Home Parenteral Nutrition
Current Trends in Home Parenteral Nutrition Jeremy Nightingale Consultant Gastroenterologist St Mark s Hospital Parenteral Routes of drug administration, which do not involve the alimentary canal Includes:
More informationDietetic Outcomes in Home Parenteral Nutrition
Dietetic Outcomes in Home Parenteral Nutrition Dr Alison Culkin Research Dietitian Intestinal Failure & Home Parenteral Nutrition St Mark s Hospital PENG Meeting November 2011 The Dietetic Outcomes Model
More informationGASTROENTEROLOGY Maintenance of Certification (MOC) Examination Blueprint
GASTROENTEROLOGY Maintenance of Certification (MOC) Examination Blueprint ABIM invites diplomates to help develop the Gastroenterology MOC exam blueprint Based on feedback from physicians that MOC assessments
More informationDietary management. Dr Alison Culkin Lead Intestinal Failure Dietitian St Mark s Hospital RSM December 2017
Dietary management Dr Alison Culkin Lead Intestinal Failure Dietitian St Mark s Hospital RSM December 2017 Overview Effect of resection on absorption Evidence for dietary management in short bowel Practicalities
More informationCurcumin and Colitis. Antioxidants and Fibromyalgia
Septmber, 2013 Volume 9, Issue 9 Better Health News2 Special Interest Articles: Heart Pregnancy and the thyroid Name that Food Iodine Hypothyroidism Vitamin D and Fibromyalgia Crohn s Disease Fibromyalgia
More informationSupplemental Table 1: Moderate and severe definitions of Celiac Disease Symptom Diary
Supplemental Table 1: Moderate and severe definitions of Celiac Disease Symptom Diary symptoms CDSD Symptom Diarrhea Constipation Abdominal Pain Bloating Nausea Tiredness Moderate Once or twice between
More informationDepartment of Gastroenterology CA-2121, Rigshospitalet, Blegdamsvej 9, DK-2100 Copenhagen, Denmark 2
Gastroenterology Research and Practice Volume 2009, Article ID 616054, 12 pages doi:10.1155/2009/616054 Clinical Study Short Bowel Patients Treated for Two Years with Glucagon-Like Peptide 2: Effects on
More informationFecal incontinence causes 196 epidemiology 8 treatment 196
Subject Index Achalasia course 93 differential diagnosis 93 esophageal dysphagia 92 95 etiology 92, 93 treatment 93 95 work-up 93 Aminosalicylates, pharmacokinetics and aging effects 36 Antibiotics diarrhea
More informationFailure to thrive - Definition. age and gender
Failure to thrive - Definition Weight or weight for height (N / M) less than two SDs below the mean for age and gender Weight curve has crossed more than two percentiles (NCHS), after having achieved a
More informationESPEN Congress The Hague 2017
ESPEN Congress The Hague 2017 Using the gut in acute care patients Permissive underfeeding in practice J.-C. Preiser (BE) PERMISSIVE UNDERFEEDING IN PRACTICE ESPEN congress Jean-Charles Preiser, M.D.,
More informationIntestinal Obstruction Clinical Presentation & Causes
Intestinal Obstruction Clinical Presentation & Causes V Chidambaram-Nathan Consultant Transplant and General Surgeon Sheffield Kidney Institute Northern General Hospital Intestinal Obstruction One of the
More informationThe Usefulness of Capsule Endoscopy
The Usefulness of Capsule Endoscopy David J. Hass, MD, FACG Associate Clinical Professor of Medicine Yale University School of Medicine Gastroenterology Center of Connecticut INDICATIONS FOR USE PillCam
More informationPractical Strategies for the Clinical Use of Incretin Mimetics CME/CE. CME/CE Released: 09/15/2009; Valid for credit through 09/15/2010
Practical Strategies for the Clinical Use of Incretin Mimetics CME/CE Robert R. Henry, MD Authors and Disclosures CME/CE Released: 09/15/2009; Valid for credit through 09/15/2010 Introduction Type 2 diabetes
More informationSheila E. Crowe, MD, FRCPC, FACP, FACG, AGAF Department of Medicine University of California, San Diego
Severe and Emergency Presentations of Celiac Disease Sheila E. Crowe, MD, FRCPC, FACP, FACG, AGAF Department of Medicine University of California, San Diego Case Presentation (1) 63 year old male transferred
More informationLearning Objectives. WOCN Richmond Oct 2016 CRParrish. I have the following relevant relationship(s) to disclose:
Seeking Enteral Autonomy: Managing the Patient with Short Bowel Syndrome Carol Rees Parrish MS, RD Nutrition Support Specialist Digestive Health Center University of Virginia Health System Charlottesville,
More informationUNC INFLAMMATORY BOWEL DISEASE DRUG PROTOCOL VEDOLIZUMAB (ENTYVIO)
UNC INFLAMMATORY BOWEL DISEASE DRUG PROTOCOL VEDOLIZUMAB (ENTYVIO) TREATMENT PROTOCOL: Vedolizumab is a humanized immunoglobulin G1 monoclonal antibody that targets 41 integrin and blocks its interaction
More informationEfficacy and Safety of Budesonide CIR versus Prednisolone in Children with Active Crohn s Disease.
CLINICAL STUDY REPORT DRUG SUBSTANCE DOCUMENT NO. VERSION NO. 01 STUDY CODE Budesonide SD-008-CR-3037 SD-008-3037 DATE 23 April, 2001 FINAL Efficacy and Safety of Budesonide CIR versus Prednisolone in
More informationThe population of subjects which was statistically analyzed was the Intent-to-Treat population
Study No.: ARIB3003 (Year 1) Title: A Randomized, Double-Blind, Placebo-Controlled, Two-Year Parallel-Group Study of the Efficacy and Safety of GI198745 in the Treatment and Modification of Progression
More informationPATHOLOGY OF NON NEOPLASTIC LESIONS OF THE UPPER GASTROINTESTINAL TRACT.
PATHOLOGY OF NON NEOPLASTIC LESIONS OF THE UPPER GASTROINTESTINAL TRACT. OESOPHAGEAL LESIONS OESOPHAGITIS AND OTHER NON NEOPLASTIC DISORDERS Corrosive Gastroesophageal reflux (GERD), Pills, Acid intake,
More informationMaking a difference in patients lives
Making a difference in patients lives building a portfolio of metabolic and gastrointestinal medicines June 2017 1 Forward-looking statements This presentation contains information pertaining to Zealand
More informationART 50 Capsules. Symptomatic treatment of functional symptoms and signs of osteoarthritis.
Doctor leaflet Art50-DL-March2012-01 ART 50 Capsules 1. NAME OF THE MEDICINAL PRODUCT Art 50 mg, capsule. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each capsule of ART 50 contains Diacerein 50 mg. For
More informationPosition of Biologics in IBD Circa 2006: Top Down vs. Step Up Therapy
Position of Biologics in IBD Circa 2006: Top Down vs. Step Up Therapy Stephen B. Hanauer, MD University of Chicago Potential Conflicts: Centocor/Schering, Abbott, UCB, Elan, Berlex, PDL Goals of Treatment
More informationEfficacy and Safety of Treatment for Pediatric IBD
Efficacy and Safety of Treatment for Pediatric IBD Andrew B. Grossman MD Co-Director, Center for Pediatric Inflammatory Bowel Disease Associate Professor of Clinical Pediatrics Division of Gastroenterology,
More informationInflammatory Bowel Diseases (IBD) Clinical aspects Nitsan Maharshak M.D., IBD Center, Department of Gastroenterology and Liver Diseases Tel Aviv Soura
Inflammatory Bowel Diseases (IBD) Clinical aspects Nitsan Maharshak M.D., IBD Center, Department of Gastroenterology and Liver Diseases Tel Aviv Sourasky Medical Center Tel Aviv, Israel IBD- clinical features
More informationNutrition Management in GI Diseases
Nutrition Management in GI Diseases Aryono Hendarto MD Nutrition & Metabolic Diseases Division Department of Child Health Cipto Mangunkusumo Hospital University of Indonesia 1 Patient s Care 1. Drugs 2.
More informationNATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Single Technology Appraisal. Canagliflozin in combination therapy for treating type 2 diabetes
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Single Technology Appraisal Canagliflozin in combination therapy for Final scope Remit/appraisal objective To appraise the clinical and cost effectiveness
More informationLA CHIRURGIA RIABILITATIVA
LA CHIRURGIA RIABILITATIVA SINDROME DA INTESTINO CORTO: GLI ASPETTI ETICI, L APPROCCIO MEDICO E LE ESIGENZE IN CAMPO NORMATIVO VII CONGRESSO NAZIONALE ASSOCIAZIONE A.N.A.D.P. UN FILO PER LA VITA ONLUS
More information